Literature DB >> 11876555

Role of alphavbeta3 integrin receptors in breast tumor.

S Sengupta1, N Chattopadhyay, A Mitra, S Ray, S Dasgupta, A Chatterjee.   

Abstract

The intriguing problem of tumor metastasis involves adhesion of the metastatic cells via the integrin group of cell surface receptors to the ECM proteins of the basement membrane. Modulation of integrin family of cell surface receptors is believed to be associated with stages of tumor metastasis. In this present study, results obtained indicate that alphavbeta3 vitronectin receptors may play an important role in the malignant behaviour of human breast tumor. Alphavbeta3 integrin receptors can modulate the activity of collagenase enzyme and thereby the invasive property of breast tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11876555

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  22 in total

1.  Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers.

Authors:  Jiyun Shi; Lijun Wang; Young-Seung Kim; Shizhen Zhai; Zhaofei Liu; Xiaoyuan Chen; Shuang Liu
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

2.  MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides.

Authors:  Orit Jacobson; Lei Zhu; Gang Niu; Ido D Weiss; Lawrence P Szajek; Ying Ma; Xilin Sun; Yongjun Yan; Dale O Kiesewetter; Shuang Liu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

3.  The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle.

Authors:  Wenwu Xiao; Yan Wang; Edmond Y Lau; Juntao Luo; Nianhuan Yao; Changying Shi; Leah Meza; Harry Tseng; Yoshiko Maeda; Pappanaicken Kumaresan; Ruiwu Liu; Felice C Lightstone; Yoshikazu Takada; Kit S Lam
Journal:  Mol Cancer Ther       Date:  2010-09-21       Impact factor: 6.261

4.  (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.

Authors:  Zi-Bo Li; Kai Chen; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-19       Impact factor: 9.236

5.  Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer.

Authors:  Shuang Liu; Young-Seung Kim; Wen-Yuan Hsieh; Subramanya Gupta Sreerama
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

Review 6.  Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.

Authors:  Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-12       Impact factor: 4.774

7.  The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling.

Authors:  Jun Saegusa; Satoshi Yamaji; Katsuaki Ieguchi; Chun-Yi Wu; Kit S Lam; Fu-Tong Liu; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2009-07-03       Impact factor: 5.157

8.  (99m)Tc-Galacto-RGD2: a novel 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging.

Authors:  Shundong Ji; Andrzej Czerwinski; Yang Zhou; Guoqiang Shao; Francisco Valenzuela; Paweł Sowiński; Satendra Chauhan; Michael Pennington; Shuang Liu
Journal:  Mol Pharm       Date:  2013-08-06       Impact factor: 4.939

9.  Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers.

Authors:  Jiyun Shi; Young-Seung Kim; Shizhen Zhai; Zhaofei Liu; Xiaoyuan Chen; Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

10.  Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.

Authors:  Lijun Wang; Jiyun Shi; Young-Seung Kim; Shizhen Zhai; Bing Jia; Huiyun Zhao; Zhaofei Liu; Fan Wang; Xiaoyuan Chen; Shuang Liu
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.